…The companies report that using Auransa’s SMarTR Engine and human disease data, they have identified a biological pathway that is predicted to be relevant and hence, likely to be important for patient outcomes… 

…Within this pathway, the companies predicted two promising protein targets…

…Using the companies’ combined technology of AI-driven biology and quantum-based chemistry, they are working on a susceptible pathway that might allow better targeting of triple-negative breast tumors and improved patient outcomes…

Editor’s Note: Italicized statements are directly quoted from the source. Content may have been edited for style and clarity. Read the full article at the source by clicking on the text or image.